BioAdaptives Inc (BDPT)

[powerbattles]

Great Question: Why isn't the company making money yet?

As of the date of this Form 10-12(g) 2019 CEO Dr. Edward E. Jacobs assumed leadership of the company as well as controlling the voting rights of our major shareholder and has since been dedicated to the development of new drugs. It is common knowledge that the process of drug development in the biotech industry often takes between 5 to 15 years, resulting in limited current revenue for most companies.
Many biotech companies list on the OTC market, develop products for many years, and still show nothing to market. However, BDPT is different. They have indicated Proven-Trusted-Success. In just a few years under Jacobs leadership, they have successfully brought many products to market, and recently, they listed full products on Amazon.

https://www.amazon.com/s?k=BIOADAPTIVES&language=en_US&linkCode=sl2&linkId=90062364c52c856ed6f0c509d276cb7f&tag=eddiesthisand-20&ref=as_li_ss_tl

The reason people are investing in this biotech stock is not solely based on its current offerings, but rather the immense potential it holds. With a series of anticipated news and press releases during the month March and April, along with the addition of new board members, licensing agreements for innovative products with patents valued at over $750 million, and upcoming spin-off, there is a significant buzz around the company. Additionally, the company's connection to artificial intelligence further adds to its allure.

Furthermore, if you view the bio of the CEO he is the INVENTOR and The DOCTOR completing surgical training at Harvard graduated the best Ivy League school in the world.
https://www.shopbioadaptives.com/blogs/news/cv

CEO Dr. Edward E. Jacobs
Patents by Inventor Edward E. Jacobs, Jr.
https://patents.justia.com/inventor/edward-e-jacobs-jr
https://podcasts.apple.com/be/podcast/natural-green-living/id1523571157?l=nl

Harvard Medical school and Princeton University. IVY Legue School ranked.

1 - HARVARD
2 - PRINCETON

https://prepexpert.com/ivy-league-school-rankings/#:~:text=Ivy%20League%20Schools%3A%20Ranked%201%201.%20Harvard%20Harvard,7%207.%20Dartmouth%20...%208%208.%20Cornell%20

This stock is truly exceptional, a golden gem in its own right. Finding such a rare and valuable opportunity is incredibly rare. The issue with other stocks is their lack of legitimacy, with many likely being scams. Let me emphasize Digging Deep to finding a gem like this one is far from easy. Our company is real and not hidden in a PO box. Our management team is top-notch, not a one-person show acting as a CEO, CFO, and COO... We boast genuine products that work exceptionally well. I tried Cell Rejuven™ for weeks, and it truly provided me with significant energy.
Our entire management team is working tirelessly without compensation until the company thrives. The CEO and directors they're already successful and retired, so they don't need to issue shares for their own gain. This rarity is unlike anything I've seen before. It's impressive that they have waived their compensation, demonstrating their commitment to retaining earnings and not simply seeking to scam our money. This is precisely why I'm dedicated to pushing forward and consistently providing thorough information for everyone to make the right choice.

Form 10-12G 2019 This is when the CEO Dr. Edward E. Jacobs taken full responsibility for the company.

ITEM 6. EXECUTIVE COMPENSATION.
Up to April 30, 2019, the following officers and director have received cash and restricted stock awards as compensation for Services since the Company’s inception. However, as of September 2018 and until the Company acquires additional capital, it is not anticipated that any officer or director will receive salary compensation from the Company other than reimbursement for out-of-pocket expenses incurred on behalf of the Company.

Form 10-k 2022 - The CEO, CFO, and President each of our officers continues waived compensation accordingly.

Item 11. Executive Compensation

We have employment agreements with our Chief Executive Officer, President and Chief Financial Officer, each of whom was to be compensated by stock grants accrued monthly based on current share prices or block grants during the period ended December 31, 2022. In consideration of the Company’s financial performance and lack of liquidity during this period, each of our officers waived compensation and we adjusted compensation accordingly.

On top of everything, we have here. Bruce Colclasure is the President of BioAdaptives’ Livestock Impact Division. We shouldn't overlook the pending spin-off of the Livestock Impact Division by the company.
Bruce Colclasure, a National Cutting Horse Association champion who owns and operates the Flying C Bar Ranch and is the breeder and trainer of over 80 NCHA champion cutting horses. Winner and owner of numerous champion horses1. He is also a judge for the National Cutting Horse Association (NCHA)

https://www.livestockimpact.com/

https://unitedstatescutting.com/hof.php

He is also the Flying C Bar Ranch Owner. https://flyingcbar.myshopify.com/

Flying C Bar Ranch Performance Horses
https://www.facebook.com/flyingcbarranch1/

FLYING C BAR RANCH VIDEO. This is a huge facility.

At last, this presents an incredibly unique opportunity, and it's astonishing that almost nobody is aware of what's unfolding here. Consider this – they've managed to secure a double-blind Human Clinical Trial, even receiving the approval from the IRB. The process of product development and obtaining approval for human clinical trials is often an extended journey, and the potential market value frequently reaches the multibillion-dollar mark. It's truly mind-boggling that our trading price remains below one penny. The situation is simply unbelievable!

CONFIRMATION—MULTIPLE STUDIES FOR MULTIPLE HUMAN CONDITIONS ALL GENERATING SUPERIOR OUTCOMES

Human Clinical Trial. The Advisory Team developed a versatile protocol that would be acceptable in the United States, Europe and Asia. An outside Clinical Data Management company was hired to do the randomization and control the data including the data collection process. Protocols for a Human Clinical trial were written and an IRB was approved. The trial was a randomized, double blind; placebo controlled Human Clinical Trial managed by an outside Clinical Data Management

https://www.shopbioadaptives.com/pages/primicell-study

"A double-blind human clinical trial is a type of research study used to test the safety and effectiveness of a new medical intervention, such as a drug or treatment. In a double-blind trial, both the participants and the researchers involved are unaware of which participants are receiving the actual treatment and which are receiving a placebo (inactive substance). This is done to eliminate bias and ensure the results are objective and reliable.

An Institutional Review Board (IRB) is an independent committee that reviews and approves the design and methods of human research studies to ensure the protection of participants' rights, safety, and well-being. Before a clinical trial can begin, it must be approved by the IRB to ensure that ethical principles are followed, and the study meets all necessary regulatory requirements. The IRB ensures that risks are minimized, and potential benefits are carefully considered before allowing the study to proceed."

My Previous DD
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172294194